Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IZERVAY™ (avacincaptad pegol intravitreal solution), a complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Product Name : Izervay
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 18, 2023
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Izervay (avacincaptad pegol intravitreal solution) act as completent C5 inhibitor that is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Product Name : Izervay
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 18, 2023
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Astellas Pharma
Deal Size : $5,900.0 million
Deal Type : Acquisition
Astellas Completes Acquisition of Iveric Bio
Details : Through the acquisition, Astellas expands its ophthalmology pipeline through Iveric Bio's promising programs, including Zimura (avacincaptad pegol), an important program for Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
Product Name : Zimura
Product Type : Oligonucleotide
Upfront Cash : $5,900.0 million
July 11, 2023
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Astellas Pharma
Deal Size : $5,900.0 million
Deal Type : Acquisition
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Astellas Pharma
Deal Size : $5,900.0 million
Deal Type : Acquisition
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
Details : Through the acquisition, Astellas will expand its ophthalmology pipeline through Iveric Bio's promising programs, including Zimura (avacincaptad pegol), an important program for Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).
Product Name : Zimura
Product Type : Oligonucleotide
Upfront Cash : $5,900.0 million
April 30, 2023
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Astellas Pharma
Deal Size : $5,900.0 million
Deal Type : Acquisition
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimura (avacincaptad pegol) is a novel complement C5 protein inhibitor having the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of geographic atrophy.
Product Name : Zimura
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimura (avacincaptad pegol) is a novel complement C5 protein inhibitor by targeting C5, ACP has the potential to decrease activity of the complement system that causes the degeneration of retinal cells and potentially slow the progression of GA.
Product Name : Zimura
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 16, 2023
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AAv-based Gene Therapy
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Opus Genetics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Opus Genetics' AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $0.5 million
December 28, 2022
Lead Product(s) : AAv-based Gene Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Opus Genetics
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimura (avacincaptad pegol), is an investigational drug that has not yet been evaluated by any regulatory body for safety and efficacy. ACP is not authorized for any indication in any country.
Product Name : Zimura
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimura (ACP) is novel complement C5 protein inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a critical role in development and growth of scarring and vision loss associated with GA secondary to AMD.
Product Name : Zimura
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimura (avacincaptad pegol) showed Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area
Product Name : Zimura
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Avacincaptad Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable